Metadon Dak

Methadone Hydrochloride, the active ingredient in Metadon Dak, is an opioid presented as an oral dosage form for oral use. It provides long‑acting analgesia and suppresses withdrawal symptoms, making it suitable for opioid dependence treatment and for managing severe chronic pain in adult patients requiring continuous opioid therapy.

GNH USA supplies Metadon Dak as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets. The company adheres to stringent manufacturing standards and provides reliable logistics support for timely delivery.

Methadone, an opioid agonist, is used in the management of conditions that involve opioid pathways, particularly where long‑acting therapy is required.

- Opioid dependence treatment: reduces withdrawal symptoms and supports maintenance therapy to help patients achieve abstinence. - Severe chronic pain: provides long‑acting analgesia for patients who need continuous opioid control. - Opioid detoxification: facilitates safe transition from short‑acting opioids during supervised withdrawal programs.

Methadone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Constipation: reduced gastrointestinal motility leading to hard stools. - Nausea: feeling of queasiness often occurring after dosing. - Drowsiness: increased sleepiness or fatigue. - Dry mouth: reduced salivation causing throat discomfort.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - QT interval prolongation: cardiac electrical disturbance that may cause arrhythmia. - Severe hypotension: marked drop in blood pressure leading to dizziness or fainting. - Anaphylactic reaction: sudden severe allergic response requiring emergency care.

When prescribing methadone, several precautions should be observed to minimize risk. - Assess respiratory function: evaluate baseline breathing and monitor for depression, especially during dose initiation. - Monitor cardiac status: obtain ECG to check QT interval and avoid use with other QT‑prolonging agents. - Use caution in hepatic impairment: adjust dosing and observe for accumulation due to reduced metabolism. - Avoid abrupt discontinuation: taper gradually to prevent precipitated withdrawal symptoms. - Evaluate for concurrent CNS depressants: limit use with benzodiazepines or alcohol to reduce respiratory risk. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Methadone interacts with several medicines; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid): - Concomitant CNS depressants (e.g., benzodiazepines, barbiturates): may cause profound respiratory depression. - Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome and hypertensive crisis. - QT‑prolonging drugs (e.g., quinidine, sotalol): additive effect on cardiac repolarization.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower methadone concentrations, reducing efficacy. - Selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline): can modestly increase methadone levels. - Alcohol: additive CNS depression, requires caution.